4.4 Article

Health-related quality of life associated with different cancer treatments in Chinese breast cancer survivors in Taiwan

期刊

EUROPEAN JOURNAL OF CANCER CARE
卷 28, 期 4, 页码 -

出版社

WILEY
DOI: 10.1111/ecc.13069

关键词

breast cancer; chemotherapy; EORTC QLQ-BR23; EORTC QLQ-C30; quality of life

资金

  1. Pfizer PFE Inc.

向作者/读者索取更多资源

We assessed the quality of life (QoL) associated with patient's characteristics and different cancer treatments among Chinese breast cancer survivors in Taiwan. A cross-sectional survey was conducted in 2017 where 193 patients with hormone receptor-positive/human epidermal growth factor receptor-2-negative metastatic breast cancer were recruited. Three QoL questionnaires were administered: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), its breast cancer supplementary measure (QLQ-BR23) and EQ-5D-5L. Multiple linear regression was performed to assess the association between QoL and cancer treatments, with adjustment for patient's characteristics. The mean age of study participants was 55.52 years. Simple linear regression showed that cancer stage and receiving chemotherapy were significantly associated with QoL scores (p < 0.05). Significant adverse effects of chemotherapy on QoL were found among early-stage cancer women (i.e., I or II), including poor cognitive and sexual functioning, and a higher symptom burden (i.e., dyspnoea, constipation, systematic therapy side effects). Multiple linear regression also revealed that receiving chemotherapy was significantly associated with poor QoL (e.g., lower functional health and higher symptom burden measured by the QLQ-BR23), compared to none chemotherapy (p < 0.05). Receiving chemotherapy was associated with poor QoL, especially among early-stage breast cancer patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Gastric Perforation Secondary to Regression of Lung Adenocarcinoma After Gefitinib Treatment

Wei-Pang Chung, Hsiang-Lin Song, Chung-Liang Ho, Nan-Tsing Chiu, Wu-Chou Su

JOURNAL OF CLINICAL ONCOLOGY (2013)

Article Medicine, General & Internal

The prognosis of early-stage breast cancer in extremely young female patients

Wei-Pang Chung, Kuo-Ting Lee, Ya-Ping Chen, Ya-Ting Hsu, Zhu-Jun Loh, Chien-Chang Huang, Hui-Ping Hsu

Summary: Extremely young breast cancer patients have poorer disease-free survival compared to older patients, but not necessarily poorer overall survival. Tumor size and triple-negative breast cancer are major prognostic factors for poorer disease-free survival in young patients. Aggressive treatment for young patients at early stages of disease can improve survival.

MEDICINE (2021)

Article Oncology

Development of the CK-MB-1 trastuzumab-resistant HER2-positive breast cancer cell line and xenograft animal models

Wei-Pang Chung, Wei-Lun Huang, Wei-An Liao, Wan-Ling Huang, You-Yu Liu, Wu-Chou Su

Summary: CK-MB-1 cells represent a stable HER2-positive trastuzumab-resistant breast cancer cell line, and their resistance does not stem from PTEN or the phosphoinositide 3-kinase signaling pathway.

CANCER MEDICINE (2021)

Article Medicine, General & Internal

Treatment-associated survival outcomes in real-world patients with de novo metastatic triple-negative breast cancer: Age as a significant treatment effect-modifier

Wei-Pang Chung, Chun-Ting Yang, Hsuan-Ying Chen, Ching-Yen Su, Hsin-Wei Su, Huang-Tz Ou

Summary: The study found that for newly-diagnosed metastatic triple-negative breast cancer (mTNBC) patients, first-line single-agent and combination chemotherapies yielded comparable survival outcomes. Younger patients may benefit more from combination regimens, while single-agent chemotherapy may be more suitable for elderly patients.

JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2022)

Article Oncology

False-negative frozen section of sentinel nodes in early breast cancer (cT1-2N0) patients

Zhu-Jun Loh, Kuo-Ting Lee, Ya-Ping Chen, Yao-Lung Kuo, Wei-Pang Chung, Ya-Ting Hsu, Chien-Chang Huang, Hui-Ping Hsu

Summary: This study investigated patients with false-negative sentinel nodes in intraoperative frozen sections (FNSN) and found that patients with larger tumor sizes and more lymphatic tumor emboli have a higher incidence of FNSN. However, the outcomes of FNSN patients after completing axillary lymph node dissection (ALND) were noninferior to those without sentinel node metastasis. ALND provides correct staging for patients with metastasis in nonsentinel axillary lymph nodes.

WORLD JOURNAL OF SURGICAL ONCOLOGY (2021)

Article Multidisciplinary Sciences

FTY720 in resistant human epidermal growth factor receptor 2-positive breast cancer

Wei-Pang Chung, Wei-Lun Huang, Wei-An Liao, Chun-Hua Hung, Chi-Wu Chiang, Chun Hei Antonio Cheung, Wu-Chou Su

Summary: FTY720 can overcome resistance to trastuzumab therapy in patients with HER2-positive breast cancer, showing potential therapeutic effects.

SCIENTIFIC REPORTS (2022)

Article Health Care Sciences & Services

Bone-targeting agents in major solid tumour metastases: a multinational cohort study

Ju Hwan Kim, Chin-Yao Shen, Philip Chun-Ming Au, Yeon-Hee Baek, Ching-Lung Cheung, Wei-Pang Chung, Nora Joelle Kleinman, Tai Chung Lam, Tzu-Chi Liao, Tzu-Chieh Lin, Ju-Young Shin, Chor-Wing Sing, Ian Chi Kei Wong, Edward Chia-Cheng Lai

Summary: This study describes the epidemiology, clinical characteristics, and utilization patterns of bone-targeting agents (BTAs) in patients with bone metastases from breast, prostate, and lung cancer. The findings show that the utilization rate of BTAs remains low in recent years and varies between different regions and tumor types.

BMJ SUPPORTIVE & PALLIATIVE CARE (2022)

Article Oncology

Comparative Treatment Persistence with Bone-Targeting Agents Among Asian Patients with Bone Metastases from Solid Tumors: A Multinational Retrospective Cohort Study

Chin-Yao Shen, Philip Chun-Ming Au, Yeon-Hee Baek, Ching-Lung Cheung, Wei-Pang Chung, Ju Hwan Kim, Nora J. Kleinman, Tai-Chung Lam, Tzu-Chi Liao, Tzu-Chieh Lin, Ju-Young Shin, Chor-Wing Sing, Ian Chi Kei Wong, Edward Chia-Cheng Lai

Summary: This study evaluated and compared the treatment persistence and re-initiation with different bone-targeting agents among Asian patients with bone metastases. The results showed that Denosumab had a lower risk of interruption compared to other bisphosphonates in Taiwan and Hong Kong, while Pamidronate had a higher risk of interruption compared to Zoledronic acid in Taiwan and Korea.

BIODRUGS (2022)

Article Medicine, General & Internal

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

J. Cortes, S. -B Kim, W. -P Chung, S. -A Im, Y. H. Park, R. Hegg, M. H. Kim, L. -M Tseng, V Petry, C. -F Chung, H. Iwata, E. Hamilton, G. Curigliano, B. Xu, C. -S Huang, J. H. Kim, J. W. Y. Chiu, J. L. Pedrini, C. Lee, Y. Liu, J. Cathcart, E. Bako, S. Verma, S. A. Hurvitz

Summary: Among patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane, trastuzumab deruxtecan was associated with a lower risk of disease progression or death compared to trastuzumab emtansine. However, treatment with trastuzumab deruxtecan was associated with interstitial lung disease and pneumonitis.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Article Rehabilitation

Real-time exercise reduces impaired cardiac function in breast cancer patients undergoing chemotherapy: A randomized controlled trial

Wei-Pang Chung, Hsin-Lun Yang, Ya-Ting Hsu, Ching-Hsia Hung, Ping-Yen Liu, Yen-Wen Liu, Shih-Hung Chan, Kun-Ling Tsai

Summary: Previous studies have shown that chemotherapy increases the risk of heart failure, but the cardioprotective effect of real-time exercise in breast cancer patients undergoing chemotherapy is unclear. In this randomized controlled study, 32 women with breast cancer were allocated to either a control group or an exercise group. The exercise group received moderate-to-high-intensity exercise training during chemotherapy and showed better cardiac function and exercise capacity compared to the control group.

ANNALS OF PHYSICAL AND REHABILITATION MEDICINE (2022)

Article Oncology

Overall survival in the OlympiA phase Ill trial of adjuvant olaparib in patients with germime pathogenic variants in BRCA1/2 and high-risk, early breast cancer

C. E. Geyer, J. E. Garber, R. D. Gelber, G. Yothers, M. Taboada, L. Ross, P. Rastogi, K. Cui, A. Arahmani, G. Aktan, A. C. Armstrong, M. Arnedos, J. Balmana, J. Bergh, J. Bliss, S. Delaloge, S. M. Domchek, A. Eisen, F. Elsafy, L. E. Fein, A. Fielding, J. M. Ford, S. Friedman, K. A. Gelmon, L. Gianni, M. Gnant, S. J. Hollingsworth, S-A Im, A. Jager, S. R. Lakhani, W. Janni, B. Linderholm, T-W Liu, N. Loman, L. Korde, S. Loibl, P. C. Lucas, F. Marme, E. Martinez de Duenas, R. McConnell, K-A Phillips, M. Piccart, G. Rossi, R. Schmutzler, E. Senkus, Z. Shao, P. Sharma, C. F. Singer, T. Spanic, E. Stickeler, M. Toi, T. A. Traina, G. Viale, G. Zoppoli, Y. H. Park, R. Yerushalmi, H. Yang, D. Pang, K. H. Jung, A. Mailliez, Z. Fan, I Tennevet, J. Zhang, T. Nagy, G. S. Sonke, Q. Sun, M. Parton, M. A. Colleoni, M. Schmidt, A. M. Brufsky, W. Razaq, B. Kaufman, D. Cameron, C. Campbell, A. N. J. Tutt, O. Th Johannsson

Summary: The OlympiA trial demonstrated that adjuvant therapy with the oral PARP inhibitor, olaparib, significantly improves overall survival in patients with gBRCA1/2pv-associated early breast cancer. The study also showed improvements in invasive disease-free survival and distant disease-free survival, with no new safety issues identified.

ANNALS OF ONCOLOGY (2022)

Article Medicine, General & Internal

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

Sara A. Hurvitz, Roberto Hegg, Wei-Pang Chung, Seock-Ah Im, William Jacot, Vinod Ganju, Joanne Wing Yan Chiu, Binghe Xu, Erika Hamilton, Srinivasan Madhusudan, Hiroji Iwata, Sevilay Altintas, Jan-Willem Henning, Giuseppe Curigliano, Jose Manuel Perez-Garcia, Sung-Bae Kim, Vanessa Petry, Chiun-Sheng Huang, Wei Li, Jean-Sebastien Frenel, Silvia Antolin, Winnie Yeo, Giampaolo Bianchini, Sherene Loi, Junji Tsurutani, Anton Egorov, Yali Liu, Jillian Cathcart, Shahid Ashfaque, Javier Cortes

Summary: In the DESTINY-Breast03 trial, trastuzumab deruxtecan showed superior progression-free survival compared to trastuzumab emtansine in patients with HER2-positive metastatic breast cancer. The study aimed to compare the efficacy and safety of trastuzumab deruxtecan versus trastuzumab emtansine. The results demonstrated that trastuzumab deruxtecan had the longest reported median progression-free survival and improved overall survival, reaffirming its role as the standard of care in the second-line setting.

LANCET (2023)

Article Oncology

Real-life analysis of neoadjuvant-therapy-associated benefits for pathological complete response and survival in early breast cancer patients-role of trastuzumab in HER2+BC and platinum in TNBC

Wei-Pang Chung, Chun-Ting Yang, Shuen-Ru Yang, Ching-Yen Su, Hsin-Wei Su, Shang-Yun Liu, Huang-Tz Ou

Summary: This study conducted a large-scale real-world investigation on the clinical outcomes of neoadjuvant treatments for patients with HER2+ and TNBC. The results showed that neoadjuvant trastuzumab significantly improved the pathological complete response (pCR) and overall survival (OS) in HER2+ patients, while platinum-based treatment increased the pCR rate but did not improve OS in TNBC patients.

FRONTIERS IN ONCOLOGY (2023)

Article Surgery

Invasive lobular carcinoma of breast with synchronous colon metastasis

Zhu-Jun Loh, Kuo-Ting Lee, Wei-Pang Chung, Wen-Chung Chen, Hsueh-Li Kuo, Po-Jun Chen, Hsi-Huei Lu, Hui-Ping Hsu

FORMOSAN JOURNAL OF SURGERY (2017)

暂无数据